bpc 157 and tp500 TB-500 10mg / BPC-157 10mg Blend BPC-157 & TB-500 Peptides for

Domestic synthesis across the catalog

Key Research Features Four-component co-lyophilized research blend four simultaneous mechanistic pathways GHK-Cu: ECM remodeling, collagen synthesis, copper coordination chemistry BPC-157: VEGFR2/Akt-eNOS angiogenic signaling, NO pathway modulation TB-500: actin sequestration, cytoskeletal dynamics, cell migration KPV: NF-B nuclear translocation inhibition via importin-3 competitive binding Fixed 50:10:10:10mg ratio single co-lyophilization run ensures uniform aliquot composition 99% RP-HPLC-verified purity per component Lyophilized powder format Suitable for in vitro and preclinical research Batch-tested for consistency Research-grade manufacturing standards Professionally labeled and documented Storage Recommendations To maintain product stability and research integrity, KLOW should be: Stored at 28C (lyophilized) or 20C (reconstituted) Reconstituted in bacteriostatic water or sterile PBS, added slowly with gentle swirling do not vortex Aliquoted immediately into single-use working volumes after reconstitution Protected from light and moisture Kept sealed until use Handled according to standard laboratory procedures Not subjected to repeated freeze-thaw cycles Toxicology and Regulatory Information All four components evaluated in preclinical toxicology and regenerative biology research models All four components designated FDA Category 2 bulk substances (503A/503B compounding lists, September 2023) Compounding by licensed 503A/503B pharmacies for human use prohibited for all four components Not evaluated by the FDA for safety or efficacy in any therapeutic application Supplied strictly as a Research Use Only (RUO) material PPE required: gloves, lab coat, protective eyewear

Last reviewed: November 16, 2025 The patients initial series is considered complete following a single dose of the Janssen COVID-19 Vaccine

This is the strongest peer-reviewed human evidence in the T4 family, although the formulation tested was full-length T4, not the TB-500 fragment used in commercial peptide products

AOD-9604 is a modest enhancer, not a transformation agent